Presentation is loading. Please wait.

Presentation is loading. Please wait.

As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach.

Published byAldous Harrison Modified over 5 years ago

Similar presentations

Presentation on theme: "As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach."— Presentation transcript:

1 As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach to dialysis care from conventional to palliative. As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach to dialysis care from conventional to palliative. Adapted from Institute of Medicine (59). Vanessa Grubbs et al. CJASN 2014;9: ©2014 by American Society of Nephrology

Download ppt "As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach."

Similar presentations

Pneumococcal pneumonia vaccinations, by unit affiliation.

Pneumococcal pneumonia vaccinations, by unit affiliation.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.

Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
What Aspects of Quality of Life Are Important From Palliative Care Patients' Perspectives? A Systematic Review of Qualitative Research  Nicola McCaffrey,

What Aspects of Quality of Life Are Important From Palliative Care Patients' Perspectives? A Systematic Review of Qualitative Research  Nicola McCaffrey,
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.
Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.

Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.
Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.

Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.
Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Similar presentations

Ads by Google